Moreover, the combination of PD-1 blockade and short-term dual inhibition of BRAF and MEK could enhance tumor immune infiltration and improved tumor regression, suggesting that a nongenomic mechanism of MAPK inhibitor resistance might mediate cross-resistance to PD-1/PD-L1 blockade therapy [92]. The gene discussed is BRAF; the disease is neoplasm.